𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

✍ Scribed by Richard J. Colonno; Ronald Rose; Carl J. Baldick; Steven Levine; Kevin Pokornowski; Cheng F. Yu; Ann Walsh; Jie Fang; Mayla Hsu; Charles Mazzucco; Betsy Eggers; Sharon Zhang; Mary Plym; Kenneth Klesczewski; Daniel J. Tenney

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
378 KB
Volume
44
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

a HBV DNA Ͻ7 ϫ 10 5 copies/mL by bDNA assay ϩ loss of HBeAg (Study AI463022) or normalization of ALT (Study AI463027).

b HBV DNA Ͻ7 ϫ 10 5 copies/mL by bDNA assay. c HBV DNA Ն7 ϫ 10 5 copies/mL by bDNA assay.

📜 SIMILAR VOLUMES

Correlation of serum hepatitis B surface
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B
✍ Myoung Hee Lee; Da Mi Lee; Soon Sun Kim; Jae Youn Cheong; Sung Won Cho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg‐positive and HBeAg

Entecavir treatment for chronic hepatiti
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
✍ Roeland Zoutendijk; Jurriën G. P. Reijnders; Ashley Brown; Fabien Zoulim; David 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV

Corrections: Entecavir treatment for chr
Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

In the August 2011 issue of HEPATOLOGY, in the article entitled ''Carcinogen-induced hepatic tumors in KLF6þ/À mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation'' (volume 54, pages 522-531), Dr.

Naturally occurring dominant resistance
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
✍ Thomas Kuntzen; Joerg Timm; Andrew Berical; Niall Lennon; Aaron M. Berlin; Sarah 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K proteas

Pre-existing YMDD mutants in treatment-n
Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy
✍ Sae Hwan Lee; Hong Soo Kim; In-Seon Byun; Soung Won Jeong; Sang Gyune Kim; Jae Y 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

## Abstract Although the rate at which mutations in the tyrosine‐methionine‐aspartate‐aspartate (YMDD) motif of hepatitis B virus polymerase form is high during prolonged lamivudine (LAM) therapy, these mutations sometimes occur naturally in treatment‐naïve patients with chronic hepatitis B. The pr